186 related articles for article (PubMed ID: 25312903)
1. E2F1 regulates p53R2 gene expression in p53-deficient cells.
Qi JJ; Liu L; Cao JX; An GS; Li SY; Li G; Jia HT; Ni JH
Mol Cell Biochem; 2015 Jan; 399(1-2):179-88. PubMed ID: 25312903
[TBL] [Abstract][Full Text] [Related]
2. Impairment of the DNA repair and growth arrest pathways by p53R2 silencing enhances DNA damage-induced apoptosis in a p53-dependent manner in prostate cancer cells.
Devlin HL; Mack PC; Burich RA; Gumerlock PH; Kung HJ; Mudryj M; deVere White RW
Mol Cancer Res; 2008 May; 6(5):808-18. PubMed ID: 18505925
[TBL] [Abstract][Full Text] [Related]
3. Disruption of the p53-p53r2 DNA repair system in ulcerative colitis contributes to colon tumorigenesis.
Yoshida T; Haga S; Numata Y; Yamashita K; Mikami T; Ogawa T; Ohkusa T; Okayasu I
Int J Cancer; 2006 Mar; 118(6):1395-403. PubMed ID: 16206288
[TBL] [Abstract][Full Text] [Related]
4. Expression and mutation analyses of P53R2, a newly identified p53 target for DNA repair in human gastric carcinoma.
Byun DS; Chae KS; Ryu BK; Lee MG; Chi SG
Int J Cancer; 2002 Apr; 98(5):718-23. PubMed ID: 11920641
[TBL] [Abstract][Full Text] [Related]
5. The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53.
Zhou B; Liu X; Mo X; Xue L; Darwish D; Qiu W; Shih J; Hwu EB; Luh F; Yen Y
Cancer Res; 2003 Oct; 63(20):6583-94. PubMed ID: 14583450
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of the p53R2 ribonucleotide reductase subunit by nitric oxide.
Guittet O; Tebbi A; Cottet MH; Vésin F; Lepoivre M
Nitric Oxide; 2008 Sep; 19(2):84-94. PubMed ID: 18474260
[TBL] [Abstract][Full Text] [Related]
7. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage.
Tanaka H; Arakawa H; Yamaguchi T; Shiraishi K; Fukuda S; Matsui K; Takei Y; Nakamura Y
Nature; 2000 Mar; 404(6773):42-9. PubMed ID: 10716435
[TBL] [Abstract][Full Text] [Related]
8. p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint.
Yamaguchi T; Matsuda K; Sagiya Y; Iwadate M; Fujino MA; Nakamura Y; Arakawa H
Cancer Res; 2001 Nov; 61(22):8256-62. PubMed ID: 11719458
[TBL] [Abstract][Full Text] [Related]
9. p53R2 inhibits the proliferation of human cancer cells in association with cell-cycle arrest.
Zhang K; Wu J; Wu X; Wang X; Wang Y; Zhou N; Kuo ML; Liu X; Zhou B; Chang L; Ann D; Yen Y
Mol Cancer Ther; 2011 Feb; 10(2):269-78. PubMed ID: 21216934
[TBL] [Abstract][Full Text] [Related]
10. p53 Suppresses E2F1-dependent PLK1 expression upon DNA damage by forming p53-E2F1-DNA complex.
Zhou Z; Cao JX; Li SY; An GS; Ni JH; Jia HT
Exp Cell Res; 2013 Dec; 319(20):3104-15. PubMed ID: 24076372
[TBL] [Abstract][Full Text] [Related]
11. Suppression of p53R2 gene expression with specific siRNA sensitizes HepG2 cells to doxorubicin.
Azimi A; Majidinia M; Shafiei-Irannejad V; Jahanban-Esfahlan R; Ahmadi Y; Karimian A; Mir SM; Karami H; Yousefi B
Gene; 2018 Feb; 642():249-255. PubMed ID: 29126924
[TBL] [Abstract][Full Text] [Related]
12. Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors.
Lin ZP; Belcourt MF; Cory JG; Sartorelli AC
J Biol Chem; 2004 Jun; 279(26):27030-8. PubMed ID: 15096505
[TBL] [Abstract][Full Text] [Related]
13. p53R2 regulates thioredoxin reductase activity through interaction with TrxR2.
Park SJ; Kim HB; Piao C; Kang MY; Park SG; Kim SW; Lee JH
Biochem Biophys Res Commun; 2017 Jan; 482(4):706-712. PubMed ID: 27866984
[TBL] [Abstract][Full Text] [Related]
14. Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits.
Xue L; Zhou B; Liu X; Qiu W; Jin Z; Yen Y
Cancer Res; 2003 Mar; 63(5):980-6. PubMed ID: 12615712
[TBL] [Abstract][Full Text] [Related]
15. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.
Link PA; Baer MR; James SR; Jones DA; Karpf AR
Cancer Res; 2008 Nov; 68(22):9358-66. PubMed ID: 19010910
[TBL] [Abstract][Full Text] [Related]
16. Expression of p53R2, newly p53 target in oral normal epithelium, epithelial dysplasia and squamous cell carcinoma.
Yanamoto S; Kawasaki G; Yoshitomi I; Mizuno A
Cancer Lett; 2003 Feb; 190(2):233-43. PubMed ID: 12565178
[TBL] [Abstract][Full Text] [Related]
17. Effect of high-risk human papillomavirus oncoproteins on p53R2 gene expression after DNA damage.
Lembo D; Donalisio M; Cornaglia M; Azzimonti B; Demurtas A; Landolfo S
Virus Res; 2006 Dec; 122(1-2):189-93. PubMed ID: 16872707
[TBL] [Abstract][Full Text] [Related]
18. Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage.
Ozaki T; Wu D; Sugimoto H; Nagase H; Nakagawara A
Cell Death Dis; 2013 Apr; 4(4):e610. PubMed ID: 23618908
[TBL] [Abstract][Full Text] [Related]
19. A ribonucleotide reductase gene is a transcriptional target of p53 and p73.
Nakano K; Bálint E; Ashcroft M; Vousden KH
Oncogene; 2000 Aug; 19(37):4283-9. PubMed ID: 10980602
[TBL] [Abstract][Full Text] [Related]
20. Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2.
Piao C; Jin M; Kim HB; Lee SM; Amatya PN; Hyun JW; Chang IY; You HJ
Oncogene; 2009 May; 28(21):2173-84. PubMed ID: 19398949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
